---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-004115"
form_type: "8-K"
ticker: "NRIX"
cik: "0001549595"
company_name: "Nurix Therapeutics, Inc."
filed_at: "2023-01-09T23:59:59+00:00"
generated_at: "2026-06-20T17:48:37.448514+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Nurix Therapeutics outlines 2023 clinical milestones for BTK degraders and CBL-B inhibitor at JPM Conference

## Summary
- NX-2127 BTK degrader: clinical update and regulatory strategy in H2 2023.
- NX-5948 BTK degrader: initial Phase 1a data and dose for expansion in H2 2023.
- NX-1607 CBL-B inhibitor: Phase 1a data and dose for expansion in H2 2023.
- Cash, equivalents and marketable securities of $413.6M as of Aug 2022; runway into Q4 2024.
- Raised $115M in 2022; expects to select new development candidate in 2023.

## SEC filing metadata
- accession: 0001193125-23-004115
- form_type: 8-K
- ticker: NRIX
- cik: 0001549595
- company_name: Nurix Therapeutics, Inc.
- filed_at: 2023-01-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1549595/000119312523004115/0001193125-23-004115-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1549595/000119312523004115/d426013d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-004115
- JSON: https://secwatch.observer/filing/0001193125-23-004115.json
- Plain text: https://secwatch.observer/filing/0001193125-23-004115.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.